Cargando…

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research

INTRODUCTION: A lack of uniformity in the choice of outcome measurement in hemophilia care and research has led to studies with incomparable results. We identified a need to define core outcome measures for use in research and clinical care of persons with hemophilia. OBJECTIVE: To move toward a cor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dover, Saunya, Blanchette, Victor S., Srivastava, Alok, Fischer, Kathelijn, Abad, Audrey, Feldman, Brian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Article: Hemostasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292657/ https://www.ncbi.nlm.nih.gov/pubmed/32548565 http://dx.doi.org/10.1002/rth2.12331

Ejemplares similares

Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates
por: Price, Victoria E., et al.
Publicado: (2021)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
por: van Balen, Erna C., et al.
Publicado: (2021)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
por: Giannis, Dimitrios, et al.
Publicado: (2021)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors
por: Shrestha, Anshu, et al.
Publicado: (2020)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen
por: Simon, Barbara, et al.
Publicado: (2022)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
por: Augustsson, Cecilia, et al.
Publicado: (2020)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
por: Pratt, Kathleen P., et al.
Publicado: (2022)

Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
por: Dover, Saunya, et al.
Publicado: (2021)

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A
por: Hiramoto, Takafumi, et al.
Publicado: (2023)

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice
por: Østergaard, Henrik, et al.
Publicado: (2021)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity
por: Wang, Michael, et al.
Publicado: (2020)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate
por: Schöchl, Herbert, et al.
Publicado: (2017)

Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
por: Thomas, Kimberly A., et al.
Publicado: (2021)

Soluble protein C receptor: why?
por: Geiger, Margarethe
Publicado: (2008)

Screening platelet function in blood donors
por: Pedini, Pascal, et al.
Publicado: (2022)

Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA‐02 and FORMA‐04 clinical trials
por: Khayat, Claudia Djambas, et al.
Publicado: (2022)

Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR
por: Manderstedt, Eric, et al.
Publicado: (2020)

Social participation and hemophilia: Self‐perception, social support, and their influence on boys in Canada
por: Chiu, Aubrey S., et al.
Publicado: (2021)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Patient selection for hemophilia gene therapy: Real‐life data from a single center
por: Krumb, Evelien, et al.
Publicado: (2021)

Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception
por: Bala, Natasha S., et al.
Publicado: (2023)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19
por: Henderson, Michael W., et al.
Publicado: (2022)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status
por: Batsuli, Glaivy, et al.
Publicado: (2021)

MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia
por: Kwak, Heechun, et al.
Publicado: (2020)

Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
por: Becattini, Cecilia, et al.
Publicado: (2021)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
por: Chan, Anthony K., et al.
Publicado: (2020)

Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation
por: Shim, Young Jun, et al.
Publicado: (2021)

Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting
por: Bakeer, Nihal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vrs1lt7v09oeqq9c69msupjk29